Cutting back on RA meds doesn't mean losing control. A new 24-week randomized trial found that gradually tapering biologic and targeted synthetic DMARDs was just as effective as continuing full-dose therapy in keeping rheumatoid arthritis patients in low disease activity. Most patients who briefly lost disease control regained it after doses were bumped back up.
Cutting back on RA meds doesn't mean losing control
A new study out of South Korea offers reassuring news for rheumatoid arthritis (RA) patients and their doctors: carefully tapering biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is just as effective as staying on full doses. The 24-week randomized trial, published in Arthritis & Rheumatology, enrolled 348 patients who had already achieved stable low disease activity (LDA) for at least 6 months.
Patients in the tapering group followed a stepwise dose reduction — subcutaneous biologics had their dosing intervals extended in two steps, while oral JAK inhibitors saw roughly a 50% dose cut. The result? Disease control was maintained at nearly identical rates in both groups, and most patients who temporarily lost LDA bounced back after doses were escalated again.
Key Takeaways
Why it matters: For patients and healthcare systems alike, tapering offers a meaningful opportunity to reduce treatment burden, side effect exposure, and costs — without sacrificing disease control, as long as close monitoring and timely dose adjustments are in place.
